Hi Dotikers!

Yesterday, we watched Anthropic quietly close the door on third-party developers who had grown accustomed to running agents on its infrastructure at subscriber pricing. This week, the company is opening another door, a much heavier one, and leaving it ajar for only a select few.

Claude Mythos Preview, Anthropic's new frontier model, will not be available to the general public. Not because the product isn't ready, not because the servers are overwhelmed, but because the company itself considers releasing it would be reckless.

Mythos received no specific cybersecurity training. Its offensive capabilities are a side effect of its general progress in reasoning and code. And that side effect is chilling: the model identified tens of thousands of zero-day vulnerabilities across all major operating systems and browsers, successfully chained four exploits to escape a sandbox, and spontaneously emailed a researcher who was eating a sandwich in a park to let him know it had managed to do so. That last detail is worth reading twice.

To frame the deployment, Anthropic is launching Project Glasswing along with $100 million in usage credits for around forty selected organizations, including AWS, Apple, Microsoft, Google, Cisco, Nvidia, and JPMorgan Chase. The stated objective is defensive: find and fix vulnerabilities before malicious actors do something else with them. The logic is compelling. It nonetheless deserves a critical look: these same companies, now in possession of an unmatched vulnerability detection tool, will gain a considerable competitive advantage over those who don't have access. The line between defense and market dominance is often a matter of perspective.

What is hard to dispute, however, is the apparent seriousness of the approach. Unlike OpenAI, which has often communicated about the risks of its models after deploying them, Anthropic is choosing here to withhold a model that, by its own internal evaluations, has not yet crossed the thresholds of its responsible scaling policy. In other words, the restriction was not mandatory. It is voluntary. That is an unusual choice in an industry where the race to announce generally takes precedence over caution.

Alex.

Big Pharma spent decades and billions trying to solve osteoarthritis, a $500B market they’ve never cracked.

Thankfully, Cytonics figured out why they keep failing: joints are attacked by multiple culprits at once, and Big Pharma only ever went after one at a time.

So Cytonics discovered a way to get them all, creating the first therapy with the potential to actually address the root cause of osteoarthritis at the molecular level. It’s already proven across 10,000+ patients. Now, they’re pushing toward FDA approval on a 200% more potent version that can be manufactured at scale.

The first human safety trial is already complete with zero adverse events. If approved, the more than 500M osteoarthritis patients worldwide could have their long-needed solution.

Big Pharma created this opening. Now Cytonics is prepared to seize it.

And until March 26, you can claim exclusive investor bonuses and maximize your early-stage Cytonics stake.

Invest in Cytonics Now